Yellow fever vaccine - Biologic Drug Details

Summary for yellow fever vaccine

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Pharmacology for yellow fever vaccine

Mechanism of Action	Osmotic Activity
Physiological Effect	Increased Large Intestinal Motility Inhibition Large Intestine Fluid/Electrolyte Absorption Actively Acquired Immunity
Established Pharmacologic Class	Osmotic Laxative Live Attenuated Yellow Fever Virus Vaccine
Chemical Structure	Vaccines, Attenuated Yellow Fever Vaccine

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for yellow fever vaccine Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for yellow fever vaccine Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for yellow fever vaccine Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Yellow Fever Vaccine

Last updated: March 1, 2026

What Drives the Market for the Yellow Fever Vaccine?

The yellow fever vaccine market is influenced by several factors. These include endemic disease outbreaks, international travel, government vaccination mandates, and global health initiatives. The vaccine remains the primary prophylactic tool against yellow fever, a viral hemorrhagic disease caused by the Flavivirus, transmitted by mosquitoes.

Key Market Drivers

• Endemic disease prevalence: Africa and parts of South America report persistently high yellow fever cases, prompting vaccination campaigns.
• International travel: Increased travel to endemic areas heightens demand for vaccinated travelers, supporting market stability.
• Global health policies: WHO and GAVI prioritize vaccination programs, increasing procurement volumes.
• Vaccine supply: The global supply chain is limited, with only a few manufacturers producing the live-attenuated 17D vaccine.

Market Constraints

• Vaccine supply shortages: Production capacity constraints lead to supply limitations.
• Cost of vaccination programs: High logistical costs hinder mass immunization, especially in low-income regions.
• Vaccine hesitancy: Concerns over safety or side effects reduce uptake in some populations.

Key Players and Market Shares

Major companies producing the yellow fever vaccine include:

Company	Market Share (Estimated)	Notable Products	Production Capacity
Sanofi Pasteur	~70%	Stamaril (not FDA-approved)	200 million doses/year
Bio-Manguinhos (Brazil)	~20%	Yellow Fever Vaccine, 17D strain	100 million doses/year
Others (including WHO prequalified manufacturers)	~10%	Various	50 million doses/year

Sanofi Pasteur holds a dominant position with its production capacity and global reach, but supply limitations persist. The Brazilian Bio-Manguinhos operates as a strategic domestic manufacturer with a focus on the South American market.

Market Size and Growth Projections

Current Market Size (2022)

• Estimated global vaccine sales: $2.2 billion
• Volume demand: Approximately 250 million doses annually

Growth trajectory

• Compound annual growth rate (CAGR): 4.5% projected from 2023 to 2030
• Drivers include increased mass vaccination campaigns in Africa and Latin America and expansion into new markets due to globalization.

Regional Market Insights

• Africa: Largest market due to endemic cases; direct government procurement and donor funding.
• South America: Growing market driven by routine immunization programs and outbreak response.
• Asia-Pacific: Emerging markets with targeted vaccination during outbreaks or travel advisories.

Financial Outlook and Investment Potential

Sanofi Pasteur’s vaccine sales exhibit stability with incremental growth. The vaccine's status as a WHO prequalified product supports international procurement agencies, such as GAVI, UNICEF, and PAHO, in securing supplies.

Investors should note:

• Production scalability projects: Sanofi announced investments aimed at increasing output by 50% over the next three years.
• R&D pipeline: Efforts toward developing thermostable formulations to reduce cold chain reliance could open new markets.
• Regulatory pathway for next-generation vaccines: Simplified approval processes for improved vaccines may accelerate commercialization.

Supply Chain and Regulatory Environment

Supply chain management remains a significant challenge. Dependence on a small supplier base creates vulnerability. Regulatory agencies in key markets—FDA, EMA, and WHO—maintain prequalification standards to ensure vaccine safety and efficacy, influencing market access.

Impact of Emerging Technologies and Strategies

Innovations include:

• Thermostable formulations: Reduce cold chain logistics costs.
• Single-dose regimens: Improve compliance and facilitate mass campaigns.
• Alternative delivery methods: Intradermal administration reduces dose volume.

These innovations could enhance vaccine coverage and expand market opportunities.

Summary of Market Dynamics

Aspect	Impact	Notes
Disease endemicity	Drives demand	Africa, South America
Supply constraints	Limiting growth	Manufacturing bottlenecks
Travel and migration	Sustains demand	Globalization effects
Policy initiatives	Provide funding	WHO, GAVI, national governments
Product innovations	Expand markets	Thermostability, dosing

Healthy growth prospects depend on overcoming manufacturing bottlenecks, expanding supply, and integrating new formulations.

Key Takeaways

• The yellow fever vaccine market was valued at ~$2.2 billion in 2022 and grows at approximately 4.5% annually.
• Sanofi Pasteur controls the majority of production capacity but faces supply limitations.
• Emerging markets and outbreak response create consistent demand, supported by international health agencies.
• Innovations like thermostable vaccines and single-dose regimens could influence future market dynamics.
• Regulatory standards and supply chain resilience critically affect the outlook.

FAQs

1. What are the main barriers to market expansion for yellow fever vaccines?
   Manufacturing constraints and supply chain limitations prevent scaling up production. Regulatory hurdles and vaccine hesitancy also impact market growth.

2. How does international aid influence the yellow fever vaccine market?
   Organizations like GAVI fund procurement in low-income countries, stabilizing demand and supporting vaccine availability.

3. Are there any efforts to develop a more effective or durable yellow fever vaccine?
   Yes. R&D is focused on thermostable formulations and single-dose vaccines to improve coverage and adherence.

4. How do regional outbreaks affect the global yellow fever vaccine market?
   Outbreaks prompt surge demand for immediate vaccination campaigns, creating short-term demand spikes.

5. What is the outlook for new entrants in this market?
   Market entry remains challenging due to limited production capacity, stringent regulatory requirements, and the established dominance of current manufacturers.

---

References

[1] World Health Organization. (2022). Yellow Fever Fact Sheet.
[2] Statista. (2022). Global Market Size of the Yellow Fever Vaccine.
[3] Sanofi Pasteur. (2023). Annual Report.
[4] Bio-Manguinhos. (2022). Production Capacity Overview.
[5] GAVI Alliance. (2022). Support for Yellow Fever Vaccination Campaigns.